Siolta Therapeutics Raises $12M in Series C Funding
Summary
Led by CEO Dr. Nikole E. Kimes, Siolta Therapeutics is a clinical-stage biotech company developing defined-consortia live biotherapeutic products that target the core drivers of disease. By leveraging its proprietary precision symbiotics platform™, Siolta advanced multiple programs into clinical and preclinical development. The company is also advancing two preclinical programs, STMC-105 and STMC-106, targeting recurrent bacterial vaginosis and necrotizing enterocolitis indications for which no FDA-approved products exist. Commenting on the news, Nikole E. Kimes said: “This Series C financing is a key step for Siolta as we continue to develop STMC-103H in the clinic. We are excited to push the boundaries of current therapeutic development, pursuing a transformative approach that targets the underlying cause of disease, and we are committed to bringing safe and effective treatment options to patients.